Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Research & Development (2016 - 2025)

International Stem Cell (ISCO) has disclosed Research & Development for 16 consecutive years, with $187000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Research & Development rose 5.65% to $187000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $634000.0, a 16.76% increase, with the full-year FY2023 number at $511000.0, up 3.86% from a year prior.
  • Research & Development was $187000.0 for Q1 2025 at International Stem Cell, roughly flat from $187000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $215000.0 in Q1 2021 to a low of $45000.0 in Q2 2023.
  • A 5-year average of $145812.5 and a median of $151000.0 in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 45.78% in 2023, then soared 84.44% in 2024.
  • International Stem Cell's Research & Development stood at $203000.0 in 2021, then plummeted by 38.42% to $125000.0 in 2022, then skyrocketed by 32.8% to $166000.0 in 2023, then rose by 12.65% to $187000.0 in 2024, then changed by 0.0% to $187000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Research & Development are $187000.0 (Q1 2025), $187000.0 (Q3 2024), and $83000.0 (Q2 2024).